(24/7 MARKET NEWS) – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced, late Friday night, that the Food and Drug Administration (FDA) approved DAYBUE (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older, making DAYBUE is the sole drug approved for the treatment of Rett syndrome.
Acadia will host a conference call Monday morning, March 13, at 8:30 a.m. Eastern Time.
To view the full release: https://www.businesswire.com/news/home/20230303005382/en/
Acadia closed Friday’s trading at $20.37, down$0.14 (-0.68%), on trading volume of 2,390,130 shares.
Its 52-week trading range is $12.24 to $28.0551.38 and it’s ideally set up for a potential huge run. If it can break through its $21.90 high, on strong volume, which is highly likely, it should challenge its 52-week high. If it breaks through that and its March 2021 $31.25 inflection point, it looks like a run to retrace the $50s, from February 2021 may be in the cards.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreprted segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
